Emerging Microbes & Infections最新文献

{"title":"Hantavirus seroprevalence and associated factors for exposure in south-central Uganda.","authors":"Gerald Katushabe, Victor Ssempijja, Deepashri Rao, Josephine Nalwadda, Kyle Rosenke, Steven J Reynolds, Jonah Omooja, Irene Andia Biraro, Mary K Grabowski, Evan A Mihalakakos, Ronald M Galiwango, Robert Ssekubugu, Denis K Byarugaba, Heinz Feldmann, David W Hawman","doi":"10.1080/22221751.2026.2665002","DOIUrl":"10.1080/22221751.2026.2665002","url":null,"abstract":"<p><p>Orthohantaviruses are largely rodent-borne pathogens that can cause haemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. In Uganda, the risk of human exposure is heightened by known rodent hosts, close human-rodent interaction in rural areas, and poor housing conditions. Despite this risk, data on human exposure remain scarce. This study sought to ascertain the seroprevalence of orthohantavirus exposure and identify associated factors with exposure among residents of the greater Masaka-Rakai region in Uganda. Seropositivity was assessed for orthohantavirus-specific IgG antibodies using commercial enzyme-linked immunosorbent assays. Logistic regression models were used to identify factors associated with seropositivity. Among 1,199 sera samples, orthohantavirus population-weighted seroprevalence was 7.4% (95% CI: 3.91-10.80). Males had a higher seroprevalence, while higher socioeconomic status was associated with a reduced burden of exposure to orthohantavirus. This study reports evidence of orthohantavirus exposure in Uganda, highlighting a previously underrecognized zoonotic risk in the region likely driven by close contact with rodent reservoirs and poor living conditions. The higher burden among males and lower-burden association with higher socioeconomic status, highlights the need for improved housing, rodent control, and integration of orthohantavirus surveillance into national public health programmes.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"15 1","pages":"2665002"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13202653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delineating the \"who-where-how\" of persistent HIV epidemics: a 23-year longitudinal genetic network, phylodynamic, and spatial analysis for precise intervention in rural China.","authors":"Yi Chen, Xiaoshan Xu, Jianjun Li, Shujia Liang, Jinghua Huang, Kailing Tang, Hui Xing, Lingjie Liao, Yi Feng, Jingjun Huang, Wanling Chen, Yuhua Ruan, Ge Zhong","doi":"10.1080/22221751.2026.2671470","DOIUrl":"10.1080/22221751.2026.2671470","url":null,"abstract":"<p><p>Despite \"Treat All\" strategies, HIV outbreaks persist among the elderly in rural Southwest China. To identify the core drivers (\"Who\"), geographic foci (\"Where\"), and socio-behavioural mechanism (\"How\") of sustained transmission in the post-\"Treat All\" era, we triangulated longitudinal genetic networks, phylodynamic and spatial analysis, and behavioural surveys using multi-source 1999-2021 data (<i>N</i> = 5094). Although antiretroviral therapy reduced community-level transmission risk by 21.0%, 107 molecular super-spreaders, predominantly males aged 50-69, were identified across four phases. These individuals exhibited poor treatment retention, with dropout rates reaching 28.2% and 38.5% having unsuppressed or missing viral loads by Phase 4. Notably, 94.4% of super-spreaders resided within 2 km of transportation arteries, exceeding 77.9% population baseline. Townships within this buffer exhibited significantly higher cumulative HIV cases independently of population metrics (adjusted Incidence Rate Ratio = 1.43, 95% CI: 1.14-1.78). Characterized as infrastructure-anchored \"risk hubs,\" these areas facilitate sustained viral dispersal through a \"double-proximity\" mechanism. Older men frequent nearby periodic markets along transit corridors for commercial sex, while female sex workers exhibit linear mobility across townships, effectively aligning their service cycles with the temporal rhythm of the periodic markets. Our methodology facilitates targeted node-level testing and interventions, bridging clinical treatment and public health prevention to mitigate aging-driven epidemics in resource-limited regions.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2671470"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13224696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and characterization of a recombinant Bundibugyo virus expressing a fluorescent reporter protein.","authors":"Shilpi Jain, Éric Bergeron, Mike Flint, Joel M Montgomery, Christina F Spiropoulou, César G Albariño","doi":"10.1080/22221751.2026.2709847","DOIUrl":"10.1080/22221751.2026.2709847","url":null,"abstract":"<p><p>Bundibugyo virus disease (BVD), caused by Bundibugyo virus (BDBV), is associated with substantial morbidity and mortality, with previous outbreaks reporting case fatality rates of 30%-50%. The ongoing BDBV outbreak in the Democratic Republic of the Congo and Uganda highlights the urgent need for virus-specific research tools and medical countermeasures. Unlike Ebola virus disease caused by Zaire ebolavirus, no licensed vaccines or specific therapeutics are currently available for BVD. The lack of research tools has limited studies with BDBV. To facilitate antiviral testing and neutralization studies, we developed the first recombinant BDBV expressing the fluorescent reporter protein ZsGreen (rBDBV-ZsG). As a proof of concept, we tested a set of previously characterized antiviral compounds and demonstrated comparable inhibitory profiles between rBDBV-ZsG and the wild-type BDBV parental strain. Furthermore, the utility of rBDBV-ZsG was successfully evaluated in neutralization assays, demonstrating robust sensitivity and specificity using monoclonal antibodies and convalescent serum samples.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2709847"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.","authors":"Hawa Sophia Bouzidi, Xavier De Lamballerie, Franck Touret","doi":"10.1080/22221751.2026.2686471","DOIUrl":"10.1080/22221751.2026.2686471","url":null,"abstract":"<p><p>Dengue virus (DENV) continues to pose a major global health challenge, with widespread distribution, frequent outbreaks, and four antigenically distinct serotypes complicating efforts for effective prevention and treatment. Despite decades of research, no universally protective vaccine or widely approved therapeutic exists, and the risk of antibody-dependent enhancement further complicates intervention strategies. This review provides an integrated perspective on dengue prevention and treatment, positioning vaccines, monoclonal antibodies, antiviral drugs, and host-directed therapies along the continuum of infection. It synthesizes recent advances in dengue prophylaxis and therapy, highlighting key innovations in vaccines, monoclonal antibodies, and antiviral compounds. Live-attenuated and chimeric tetravalent vaccines have progressed from early development to advanced clinical trials, demonstrating promising immunogenicity, safety, and potential for simplified dosing regimens. Concurrently, engineered monoclonal antibodies targeting conserved viral epitopes have improved neutralization breadth and reduced enhancement risk, while combination strategies may further limit viral escape. Antiviral development has explored both direct-acting and host-directed mechanisms, revealing potent candidates in preclinical models, although clinical translation remains challenging. Together, these advances illustrate a multifaceted approach to dengue control, integrating vaccine optimization, rational antibody design, and targeted therapeutics. By contextualizing recent progress and remaining challenges, this review underscores the urgent need for coordinated efforts to develop safe, effective, and broadly deployable interventions, ultimately supporting global efforts to reduce the burden of dengue.<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT04722627, NCT05201794, NCT06006559, NCT05710224, NCT04273217.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2686471"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seminal fluid enhances monkeypox virus infection via amyloidogenic fibrils.","authors":"Emma Torbica, Matthias Denkewitz, Tamara Quick, Nadja Zöller, Katja Steinhorst, Stefan Kippenberger, Florian Rothweiler, Jindrich Cinatl, Pia Veratti, Florian Full, Undraga Schagdarsurengin, Sandra Ciesek, Jan Münch, Janis A Müller, Denisa Bojkova","doi":"10.1080/22221751.2026.2703396","DOIUrl":"10.1080/22221751.2026.2703396","url":null,"abstract":"<p><p>Mpox is a re-emerging zoonosis caused by monkeypox virus (MPXV), with recent outbreaks driven by sexual transmission. How semen contributes to MPXV infection, however, remains unclear. Here, we show that human seminal fluid potently enhances MPXV infection in susceptible target cells. Pre-exposure of MPXV to seminal fluid from multiple donors markedly increased infection of primary human fibroblasts and keratinocytes. Semen-derived peptide fragments that assemble into cationic amyloid fibrils (SEVI and SEM) enhanced infection of epithelial cells, primary monocytes, and ex vivo human skin, as well as clinical MPXV isolates and other <i>orthopoxviruses</i>. SEVI increased virion attachment and uptake, and fibril-targeting molecular tweezer (CLR01) disrupted seminal amyloids and abrogated enhancement. Notably, tecovirimat and brincidofovir retained activity under SEVI-enhanced conditions. These findings identify seminal amyloids as host factors that amplify MPXV infectivity and broaden cell tropism, suggesting that semen actively promotes sexual transmission of mpox.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"15 1","pages":"2703396"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experimental evolution of phage K enhances antibacterial activity against USA300 MRSA in lung infection models.","authors":"Swanti Schapp, Paula Seibold, Yasmina Reisser, Niklas Kühn, Franziska Hornung, Mara Lohde, Christian Brandt, Sandor Nietzsche, Bettina Löffler, Stefanie Deinhardt-Emmer","doi":"10.1080/22221751.2026.2724634","DOIUrl":"10.1080/22221751.2026.2724634","url":null,"abstract":"<p><p>Hypervirulent community-associated MRSA clones such as <i>Staphylococcus aureus</i> (<i>S. aureus</i>) USA300 drive rapidly progressive necrotizing pneumonia with high morbidity and limited therapeutic options. Bacteriophage K (phage K) is a well-characterized lytic phage active against <i>S. aureus</i>, but its efficacy is limited by restricted host range and the emergence of bacterial resistance. Here, we subjected phage K to experimental evolution on <i>S. aureus</i> USA300 to select an adapted variant with enhanced bactericidal properties. Wild-type phage K and the evolved derivative, designated phage KJ25, were compared using growth inhibition assays, time-kill kinetics, genomic differences and transcriptomic analyses of the bacterial response to infection. Efficacy was evaluated in an <i>in vitro</i> A549 lung epithelial cell infection model and <i>ex vivo</i> murine precision-cut lung slices (PCLS). Phage KJ25 exhibited significantly improved killing of USA300, achieving faster bacterial reduction and sustained suppression of regrowth. Genomic analysis identified a function-impairing mutation in gene <i>gp102</i>, encoding a predicted DNA-binding protein implicated in transcriptional regulation. RNA sequencing revealed that KJ25 infection of USA300 induced a slower and less disruptive host transcriptional takeover than wild-type phage K. Importantly, in both A549 cells and PCLS model, phage KJ25 markedly reduced bacterial burden while preserving lung tissue integrity, supporting its therapeutic potential. Collectively, these findings highlight the value of experimental evolution for tailoring therapeutic phages and support phage adaptation as a promising strategy for developing interventions against multidrug-resistant <i>S. aureus</i>.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2724634"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13552335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral human mAb therapy yields modulation of neuroinflammation and long-term functional recovery from lyssavirus infection.","authors":"Celeste Huaman, Yan Xu, Nathaniel M Lott, Elise M Santorella, Madeline Rader, Allison M Strazzella, Caitlyn Clouse, Jocelyn M King, Mattie Melnyk, Junping Hong, Lianying Yan, Adrian C Paskey, Andrea E Luquette, Francisco Malagon, Regina Z Cer, Kimberly A Bishop-Lilly, Daniel P Perl, Christopher C Broder, Kai Xu, Brian C Schaefer","doi":"10.1080/22221751.2026.2736987","DOIUrl":"10.1080/22221751.2026.2736987","url":null,"abstract":"<p><p>Rabies is a fatal encephalitis caused by viruses in the lyssavirus genus. We previously demonstrated that intraperitoneal administration of a single dose of neutralizing human monoclonal antibody (mAb) F11 can protect mice from fatal lyssavirus infection, post-central nervous system (CNS) invasion. However, the molecular basis of F11 neutralization remains unknown. Here, we use structural and functional analyses to define neutralizing activity of F11 and the related mAb, A6. Cryo-electron microscopy (EM) and negative-stain EM reveal that both mAbs bind Domain III of the glycoprotein G, recognizing a prefusion-specific epitope distinct from previously characterized antibodies including RVC20. Binding stabilizes the prefusion state, blocking membrane fusion. We furthermore found that a single dose of either A6 or RVC20 protected animals from mortality induced by Australian bat lyssavirus (ABLV), while promoting substantial long-term functional recovery. Moreover, A6 similarly protected animals from mortality following infection with a currently circulating wild isolate of <i>rabies virus</i> (RABV). Transcriptomics analysis of brain RNA and protein-based analysis of brain tissue homogenates demonstrated that therapy with A6 broadly reduced expression of neuroinflammatory mediators during the acute phase of infection. Interestingly, infection of animals with a non-lethal attenuated mutant of ABLV resulted in similar neuroinflammation. Thus, a robust neuroinflammatory response to ABLV does not predict mortality. Overall, peripheral therapy with A6 and similar neutralizing mAbs promotes survival and long-term functional recovery from CNS-resident lyssavirus infection in a manner that includes suppression of the G pre- to postfusion transition and modulation of neuroinflammation.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2736987"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13637774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A universally conserved OMV-YidR conjugate nanovaccine confers broad protection against hypervirulent and carbapenem-resistant <i>Klebsiella pneumoniae</i>.","authors":"Shuangjun He, Yang Zhang, Ahui Song, Chenyu Fan, Feng Zhao, Wei Zhou, Cuiying Xie, Chu Guo, Shengliang Chen, Yi Chen","doi":"10.1080/22221751.2026.2731500","DOIUrl":"10.1080/22221751.2026.2731500","url":null,"abstract":"<p><p>The escalating crisis of multi-drug resistant (MDR) <i>Klebsiella pneumoniae</i> (KP) renders standard antibiotic treatments increasingly ineffective, necessitating a shift towards alternative approaches like vaccination. However, the development of a broadly protective vaccine remains hindered by the pathogen's extensive serotype diversity. To overcome this limitation, we targeted YidR - a highly conserved protein with potential as a universal antigen - and engineered a semi-synthetic conjugate vaccine by covalently linking it to KP-derived outer membrane vesicles (OMVs). The OMV-YidR conjugate successfully overcame the poor intrinsic immunogenicity of soluble YidR, eliciting robust antigen-specific IgG titres >20,000-fold higher than the unconjugated protein. Furthermore, the conjugate vaccine drove a shift from a weak Th2 bias to a potent, protective Th1/Th17 cellular profile. Crucially, this enhanced immunogenicity translated into broad-spectrum efficacy: while unconjugated OMVs protected only against the homologous strain, the OMV-YidR conjugate conferred complete (100%) survival against lethal challenges with diverse clinical isolates, including hypervirulent and carbapenem-resistant lineages. Mechanistic and comparative analyses revealed that covalent linkage - rather than simple physical co-administration - was essential for this superior efficacy, which was correlated with the preferential trafficking and uptake of the antigen by B cells in the draining lymph nodes. These findings establish the OMV-YidR conjugate as a highly potent, universal vaccine candidate capable of bypassing serotype limitations to prevent untreatable MDR <i>K. pneumoniae</i> infections.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2731500"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13587577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lethal C57BL/6 mouse model for Yezo virus infection and antiviral therapeutic evaluation.","authors":"Yu Liu, Ning Liu, Ge Zhang, Ziyan Liu, Tinglan Ji, Liang Li, Zedong Wang","doi":"10.1080/22221751.2026.2731505","DOIUrl":"10.1080/22221751.2026.2731505","url":null,"abstract":"<p><p>Yezo virus (YEZV) is an emerging tick-borne orthonairovirus that causes febrile illness and hepatic injury in humans. However, its pathogenesis and effective antiviral interventions remain poorly characterized. In this study, we generated a lethal, mouse-adapted YEZV strain through 30 serial passages in C57BL/6 mice. The adapted strain successfully recapitulated key clinical and pathological features of human YEZV infection, including leukopenia, thrombocytopenia, and hepatitis, as evidenced by elevated serum transaminases, high hepatic viral loads, and histopathological necroinflammatory lesions. Notably, female mice exhibited significantly higher mortality than males, revealing a sex-associated difference in disease susceptibility. Antiviral evaluation demonstrated that both favipiravir and ribavirin significantly suppressed in vivo YEZV replication, improved survival, and reduced hepatic viral burden. Collectively, this model establishes a rigorously validated platform for mechanistic studies of YEZV pathogenesis and the preclinical evaluation of antiviral therapeutics.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2731505"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13587542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we escape from top-priority ESKAPE pathogens?","authors":"Lingbing Zeng, Youjun Feng, Minggui Wang","doi":"10.1080/22221751.2026.2614739","DOIUrl":"10.1080/22221751.2026.2614739","url":null,"abstract":"<p><p><b>ABSTRACT</b>The ESKAPE pathogens - <i>Enterococcus faecium</i>, <i>Staphylococcus aureus</i>, <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Enterobacter spp.</i> - are designated by the World Health Organization as critical-priority multidrug-resistant organisms. These bacteria are leading contributors to the global antimicrobial resistance crisis, significantly increasing morbidity, mortality, and healthcare costs worldwide. Their capacity to evade conventional antibiotics continues to complicate clinical management and undermine infection control efforts. Tackling the global threat of ESKAPE pathogens demands coordinated and sustained interventions. This mini review summarizes recent evidence on the burden and prevalence of ESKAPE infections and assesses emerging strategies to combat resistance. Progress in surveillance and promising preclinical and clinical studies of novel therapies underscore that integrated approaches are crucial. Moving forward, a balanced emphasis on prevention, surveillance, and therapeutic innovation will be essential to mitigating the threat posed by ESKAPE pathogens over the coming decade.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2614739"},"PeriodicalIF":7.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}